ECWM-2

Study Design: Phase II, single arm, multicenter, international

Patients: treatment naive WM patients

Treatment: Bortezomib-Rituximab-Ibrutinib

Status of the Study: patient recruitment closed (last patient in November 2021, n= 53)

Sponsor: University Hospital of Ulm, PI Christian Buske